Business
CHOSA: Q2 loss narrowed and cash reserves grew as CHOSA advanced oncology partnerships and technology
CHOSA: Q2 loss narrowed and cash reserves grew as CHOSA advanced oncology partnerships and technology
About this update from Chosa Oncology Ab
CHOSA Oncology reduced its Q2 loss year-over-year, strengthened its cash position, and advanced its cisplatin-DRP and LiPlaCis programs, supported by a recent share issue and growing industry recognition.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.